Nothing Special   »   [go: up one dir, main page]

Calarese, 2006 - Google Patents

Structural studies of HIV-1 neutralizing antibody 2G12

Calarese, 2006

Document ID
746369827833267081
Author
Calarese D
Publication year

External Links

Snippet

With no cure on the horizon, there is widespread agreement that an HIV-1 vaccine is necessary to help slow the AIDS pandemic. A small panel of potent, broadly-neutralizing HIV- 1 antibodies has been isolated from infected individuals. In passive infusion studies …
Continue reading at search.proquest.com (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse Transcribing RNA Viruses
    • C12N2740/00011—Reverse Transcribing RNA Viruses
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4

Similar Documents

Publication Publication Date Title
Burton et al. Broadly neutralizing antibodies to HIV and their role in vaccine design
Zwick et al. Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120
Binley et al. Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization
Wang Synthetic carbohydrate antigens for HIV vaccine design
CA2504755C (en) Carbohydrate-based synthetic vaccines for hiv
Pantophlet et al. GP120: target for neutralizing HIV-1 antibodies
EP2765138B1 (en) HIV-1 envelope glycoprotein
Zwick et al. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12
Fernandez-Tejada et al. Designing synthetic vaccines for HIV
Delhalle et al. Phages and HIV-1: From display to interplay
Prabakaran et al. Structure and function of the HIV envelope glycoprotein as entry mediator, vaccine immunogen, and target for inhibitors
Sirois et al. Glycosylation of HIV-1 gp120 V3 loop: towards the rational design of a synthetic carbohydrate vaccine
Lekkerkerker et al. Potency of HIV-1 envelope glycoprotein gp120 antibodies to inhibit the interaction of DC-SIGN with HIV-1 gp120
Liu et al. Altering the Specificity of the Antibody Response to HIV gp120 with a Glycoconjugate Antigen
Calarese Structural studies of HIV-1 neutralizing antibody 2G12
JP5746149B2 (en) Antiviral carbohydrate binding module compositions and methods of use
US20110124842A1 (en) Peptide that binds to a broadly neutralizing anti-HIV antibody-structure of 4E10 Fab fragment complex, uses thereof, compositions therefrom
Kong et al. Toward a carbohydrate-based HIV-1 vaccine
Gift et al. Conformational and structural features of HIV-1 gp120 underlying the dual receptor antagonism by cross-reactive neutralizing antibody m18
Murrell Structural Evolution of Broadly Neutralizing Antibodies Against HIV During Natural Infection
Altman The Role of Ultralong Antibody Loops in the Recognition of HIV Studied by Immunization of Cows
Pashov et al. Carbohydrate targets in HIV vaccine research: lessons from failures
Omorodion Broadly Neutralizing Antibodies to HIV: Evolution of Structure in Three Infected Donors
Pauthner Immune Responses to HIV Following Natural Infection and Vaccination
Cottrell Structure-Based HIV Immunogen Design